Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Colon Cancer treatment details. Chemotherapy. Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

Survival: 17.4 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: Netherlands
City/State/Province: Nijmegen
Hospital: Radboud University Nijmegen Medical Centre
Journal: Link
Date: 7/2007

Patients: This study involved 803 patients with advanced colorectal cancer. Twenty-two percent were older than 70 years and the median age was 63, ranging from 27 to 84.
Most (63%) were men.

Treatment: Patients were randomly divided into two groups and given the chemotherapy drugs capecitabine, irinotecan, and oxaliplatin. The difference between the two groups was how the drugs were given. In the combination group, patients were given capecitabine with irinotecan and then capecitabine and oxaliplatin. The sequential group, patients were given capecitabine, then irinotecan, then capecitabine with oxaliplatin.

Toxicity: Eleven patients died from causes likely related to treatment. The causes of death were sepsis, diarrhea, and neutropenic fever. Eight of these deaths occurred in the sequential treatment group and three in the combination treatment group.

Results: The median overall survival was 17.4 months in patients receiving the combination treatment and 16.3 for the sequential treatment group. This difference was not significantly different.

Support: Research funds from Roche, Aventis, Sanofi, and Pfizer were provided. Capecitabine is marketed by Hoffmann-La Roche as Xeloda, and oxaliplatin is marketed by Sanofi-Aventis as ELOXATIN (oxaliplatin injection). Irinotecan is marketed as CAMPTOSAR® (irinotecan HCI injection) by Pfizer.

Correspondence: Dr. Cornelis J. A. Punt

E-mail to a Friend Email Physician More Information